The Use of Real‐World Evidence for Regulatory Decisions in China,Clinical Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Clin. Pharmacol. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The Use of Real‐World Evidence for Regulatory Decisions in China
Clinical Pharmacology & Therapeutics ( IF 6.7 ) Pub Date : 2024-04-03 , DOI: 10.1002/cpt.3257
Jiayue Xu _{1,

2,

3} , Wenkai Wu _{1,

2,

3} , Xia Zhang _{1,

2,

3} , Yan Ren _{1,

2,

3} , Minghong Yao _{1,

2,

3} , Mei Liu _{1,

2,

3} , Kang Zou _{1,

2,

3} , Wen Wang _{1,

2,

3} , Xin Sun _{1,

2,

3}

Affiliation

There is a growing demand for the use of high‐quality real‐world evidence (RWE) to support regulatory decision‐making worldwide and in China, which highlights the need for conducting literature reviews to evaluate the available data and evidence. This study aims to review the use of RWE in Chinese regulatory decisions and to summarize relevant regulatory and methodological considerations to inform the future use of RWE in China. We identified policy documents, technical guidance documents, and cases on official Chinese government websites and extracted their contents separately. We consulted experts from the National Medical Products Administration (NMPA) and academic institutes and searched case‐related articles for enrichment. We also searched and included articles related to the use of RWE/Real‐world data in Chinese regulatory decisions. Six trial versions of technical guidance documents, 7 case studies, and 40 articles related to the Chinese regulatory decisions were included in this study. Based on the technical guidance, data quality, and appropriate study design and statistical analysis are the main concerns for RWE generation. The cases and articles related to regulatory decisions revealed 9 main concerns, including data sources and applicability, data quality, strength of existing evidence, appropriate study design and statistical analysis, regulated and transparent process for analysis and evidence generation, product safety and efficacy, product characteristics and clinical needs, ethical considerations and data security, and communicate adequately with regulatory authorities. Among these concerns, data issues are central. Preliminary attempts have been made by the NMPA to promote the use of RWE, but substantial challenges still remain.

更新日期：2024-04-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>